**Author details**

Roxana Rodríguez-Barrera, Marcela Garibay-López and Antonio Ibarra\* Centro de Investigación en Ciencias de la Salud (CICSA), Universidad Anáhuac México Campus Norte, Huixquilucan, Estado de México, México

\*Address all correspondence to: jose.ibarra@anahuac.mx

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**173**

*Trends in Neuroprotective Strategies after Spinal Cord Injury: State of the Art*

[9] Kim YH, Ha KY, Kim SI. Spinal cord injury and related clinical trials. Clinics in Orthopedic Surgery. 2017;**9**(1):1-9

Yilmaz T. Current and future surgery strategies for spinal cord injuries. World Journal of Orthopedics. 2015;**6**(1):34-41

[11] Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala DB, et al. Acute spinal cord injury, part I: Pathophysiologic mechanisms. Clinical Neuropharmacology.

[10] Dalbayrak S, Yaman O,

2001;**24**(5):254-264

[12] Mautes AE, Weinzierl MR, Donovan F, Noble LJ. Vascular events after spinal cord injury: Contribution to secondary pathogenesis. Physical Therapy. 2000;**80**(7):673-687

[13] Hilton BJ, Moulson AJ, Tetzlaff W. Neuroprotection and secondary damage following spinal cord injury: Concepts and methods. Neuroscience Letters. 2017;**652**:3-10

[14] Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: A nugget of this multiply cascade. Acta Neurobiologiae Experimentalis (Wars). 2011;**71**(2):281-299

[15] Hulsebosch CE. Recent advances in pathophysiology and treatment of spinal cord injury. Advances in Physiology Education. 2002;**26**(1-4):238-255

[16] von Euler M, Li-Li M, Whittemore S, Seiger A,

in experimental spinal cord injuries. Journal of Neurotrauma.

1997;**14**(1):53-61

2018;**16**(10):352

Sundstrom E. No protective effect of the NMDA antagonist memantine

[17] Melnikova DI, Khotimchenko YS, Magarlamov TY. Addressing the issue of tetrodotoxin targeting. Marine Drugs.

*DOI: http://dx.doi.org/10.5772/intechopen.89539*

Kotter MRN, Druschel C, Curt A, et al. Traumatic spinal cord injury. Nature Reviews. Disease Primers. 2017;**3**:17018

[2] Rowland JW, Hawryluk GW, Kwon B, Fehlings MG. Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. Neurosurgical Focus.

[1] Ahuja CS, Wilson JR, Nori S,

[3] Zhou Y, Wang Z, Li J, Li X, Xiao J. Fibroblast growth factors in the management of spinal cord injury. Journal of Cellular and Molecular Medicine. 2018;**22**(1):25-37

[4] Lenehan B, Street J, Kwon BK, Noonan V, Zhang H, Fisher CG, et al. The epidemiology of traumatic spinal cord injury in British Columbia, Canada. Spine (Phila Pa 1976).

[5] Chen Y, He Y, DeVivo MJ. Changing demographics and injury profile of new traumatic spinal cord injuries in the United States, 1972-2014. Archives of Physical Medicine and Rehabilitation.

[6] van den Berg ME, Castellote JM, Mahillo-Fernandez I, de Pedro-Cuesta J.

Carreon-Rodriguez A, Parra-Cid del C, Leon CI, Velasquillo-Martinez C, Vacanti CA, et al. Spinal cord injury and regenerative medicine. Salud Pública de

Incidence of spinal cord injury worldwide: A systematic review. Neuroepidemiology. 2010;**34**(3):184-

2008;**25**(5):E2

**References**

2012;**37**(4):321-329

2016;**97**(10):1610-1619

192; discussion 92

[7] Estrada-Mondaca S,

México. 2007;**49**(6):437-444

[8] Rouanet C, Reges D, Rocha E, Gagliardi V, Silva GS. Traumatic spinal cord injury: Current concepts and treatment update. Arquivos de Neuro-Psiquiatria. 2017;**75**(6):387-393

*Trends in Neuroprotective Strategies after Spinal Cord Injury: State of the Art DOI: http://dx.doi.org/10.5772/intechopen.89539*
